转移性黑色素瘤的系统性治疗新范例。
The new paradigm of systemic therapies for metastatic melanoma.
机构信息
Department of Internal Medicine, Division of Oncology's Neag Cancer Center, University of Connecticut Health Center, Farmington, Connecticut.
Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut.
出版信息
J Am Acad Dermatol. 2017 Aug;77(2):356-368. doi: 10.1016/j.jaad.2017.04.1126.
New treatments for metastatic melanoma work through distinct mechanisms: enhancing the immune response and blocking cellular proliferation. Agents that enhance the immune response include ipilimumab, pembrolizumb, and nivolumab; agents that block cellular proliferation include vemurafenib, dabrafenib, trametinib, cobimetinib, binimetinib, and selumetinib. The translational impact of laboratory discoveries has revolutionized management of metastatic melanoma and enhanced the prognosis of affected patients.
转移性黑色素瘤的新疗法通过不同的机制发挥作用
增强免疫反应和阻断细胞增殖。增强免疫反应的药物包括伊匹单抗、派姆单抗和纳武单抗；阻断细胞增殖的药物包括威罗菲尼、达拉非尼、曲美替尼、考比替尼、比美替尼和塞尔美替尼。实验室发现的转化影响彻底改变了转移性黑色素瘤的治疗方法，并改善了受影响患者的预后。
Zotero 插件